Core Viewpoint - Coeptis Therapeutics Holdings, Inc. will implement a 1-for-20 reverse stock split to comply with Nasdaq Capital Market listing requirements, following approval from its board and stockholders [1][4][5] Group 1: Reverse Stock Split Details - The reverse stock split will convert every 20 shares of the Company's common stock into one share, with no fractional shares issued; any resulting fractions will be rounded up to the next whole number [3] - The effective date for the reverse stock split is December 31, 2024, marking the first day of trading on a post-split basis [2][3] Group 2: Purpose and Approval - The reverse stock split aims to help the Company meet the minimum bid price requirement of $1.00 per share as mandated by Nasdaq rules [4] - The reverse split was approved at the Company's Annual Stockholder's Meeting on December 18, 2024, after which the board established the split ratio [5] Group 3: Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [7] - The Company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR technology licensed from the University of Pittsburgh [7]
Coeptis Therapeutics Announces Reverse Stock Split